Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition

Yvonne Puplampu-Dove, Tal Gefen, Anugraha Rajagopalan, Darija Muheramagic, Brett Schrand, Eli Gilboa

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

TGFβ secreted by tumor cells and/or tumor infiltrating stromal cells is a key mediator of tumor growth and immune suppression at the tumor site. Nonetheless, clinical trials in cancer patients targeting the TGFβ pathway exhibited at best a modest therapeutic benefit. A likely reason, a common limitation of many cancer drugs, is that the physiologic roles of TGFβ in tissue homeostasis, angiogenesis, and immune regulation precluded the dose escalation necessary to achieve a profound clinical response. Murine studies have suggested that countering immune suppressive effects of TGFβ may be sufficient to inhibit tumor growth. Here we describe an approach to render vaccine-activated CD8+ T cells transiently resistant to TGFβ inhibition using an siRNA against Smad4 to inhibit a key step in the canonical TGFβ signaling pathway. The siRNA was targeted to vaccine activated CD8+ T cells in the mouse by conjugation to a 4–1BB binding oligonucleotide (ODN) aptamer ligand (4–1BB-Smad4 conjugate). In vitro the 4–1BB-Smad4 conjugate rendered T cells partially resistant to TGFβ inhibition, and treatment of tumor bearing mice with systemically administered 4–1BB-Smad4 conjugate enhanced vaccine- and irradiation-induced antitumor immunity. Limiting the inhibitory effects of TGFβ to tumor-specific T cells will not interfere with its multiple physiologic roles and hence reduce the risk of toxicity.

Original languageEnglish (US)
JournalOncoImmunology
DOIs
StateAccepted/In press - Feb 14 2018

    Fingerprint

Keywords

  • Aptamers
  • Cancer immunotherapy
  • preclinical mouse models
  • siRNA
  • TGFβ
  • tumor targeting

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this